Spyre Therapeutics (SYRE) Cash from Investing Activities (2015 - 2026)
Spyre Therapeutics (SYRE) posted Cash from Investing Activities of $56.6 million for Q1 2026, up 122.87% on a QoQ basis from -$247.4 million in Q4 2025, and up 92855.74% year-over-year from N/an in Q1 2025.
Spyre Therapeutics (SYRE) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $56.6 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 92855.74% year-over-year to $56.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$86.8 million (up 65.04% YoY) and the FY2025 annual result came in at -$143.5 million, up 59.39% from the prior year.
- Cash from Investing Activities was $56.6 million for Q1 2026 at Spyre Therapeutics, up from -$247.4 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $79.0 million in Q2 2025 and bottomed at -$247.4 million in Q4 2025.
- A 5-year average of -$28.9 million and a median of $6.8 million in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities plunged 1882.81% — and 2026, when it soared 92855.74%.
- Spyre Therapeutics' Cash from Investing Activities stood at $14.0 million in 2022, then sank by 351.94% to -$35.3 million in 2023, then sank by 383.51% to -$170.5 million in 2024, then sank by 45.07% to -$247.4 million in 2025, then surged by 122.87% to $56.6 million in 2026.
- Business Quant data shows SYRE's Cash from Investing Activities at $56.6 million in Q1 2026, -$247.4 million in Q4 2025, and $25.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Spyre Therapeutics | 259.59 Mn | 259.59 Mn | - | 56.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.58 Mn |
| Mar 31, 2026 | 56.58 Mn |
| Dec 31, 2025 | -247.41 Mn |
| Dec 31, 2025 | -247.41 Mn |
| Sep 30, 2025 | 25.00 Mn |
| Sep 30, 2025 | 25.00 Mn |
| Jun 30, 2025 | 79.00 Mn |
| Jun 30, 2025 | 79.00 Mn |
| Mar 31, 2025 | -61,000.00 |
| Mar 31, 2025 | -61,000.00 |
| Dec 31, 2024 | -170.54 Mn |
| Dec 31, 2024 | -170.54 Mn |
| Sep 30, 2024 | 42.74 Mn |
| Sep 30, 2024 | 42.74 Mn |
| Jun 30, 2024 | -120.52 Mn |
| Jun 30, 2024 | -120.52 Mn |
| Mar 31, 2024 | -104.96 Mn |
| Mar 31, 2024 | -104.96 Mn |
| Dec 31, 2023 | -35.27 Mn |
| Dec 31, 2023 | -35.27 Mn |